The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

Department of Gynecology and Obstetrics, Johann Wolfgang Goethe-University, Frankfurt am Main.
Annals of Oncology (Impact Factor: 7.04). 08/2012; 23(10):2605-2612. DOI: 10.1093/annonc/mds203
Source: PubMed


Despite recent progress in the treatment of ovarian cancer, the majority of patients eventually relapse. There is little information on the effectiveness of chemotherapy in higher treatment lines.

Patients and methods:
Characterization of the second to sixth line therapy and its effects on survival was carried out, based on data of n = 1620 patients from three large randomized phase III trials investigating primary therapy.

Median progression-free survival (PFS) after the first, second, third, fourth and fifth relapse was 10.2 [95% confidence interval (CI) 9.6-10.7], 6.4 (5.9-7.0), 5.6 (4.8-6.2), 4.4 (3.7-4.9) and 4.1 (3.0-5.1) months, respectively. Median overall survival (OS) after the first, second, third, fourth and fifth relapse was 17.6 (95% CI 16.4-18.6), 11.3 (10.4-12.9), 8.9 (7.8-9.9), 6.2 (5.1-7.7) and 5.0 (3.8-10.4) months, respectively. The most frequent second and third line chemotherapy was platinum combination (n = 313, 24.5%) and topotecan (n = 118, 23.6%), respectively. Relapse treatment improved PFS and OS at the second to fourth recurrence, although frequently not performed according to the standard of care. In multivariate analysis, platinum sensitivity and optimal primary tumor debulking were revealed as independent prognostic factors for PFS up to third relapse.

A maximum of three lines of subsequent relapse treatment seems to be beneficial for patients with recurrent ovarian cancer. Optimal primary tumor debulking and platinum sensitivity remain independent prognostic factors even after more frequent relapses.

  • Source
    • "Results based on UBS Warburg market share data demonstrated mean costs for chemotherapy treatment were $48,758 for patients treated empirically (no assay), $33,187 for patients with assay results available (65 % adhered to assay results), and $23,986 for patients modeled to have 100 % adherence to assay results. Spanning the median OS of 44 months, the majority of EOC patients experience multiple episodes of disease recurrence [6]. Therefore, treatment costs typically include both surgery and multiple chemotherapy interventions [61]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The objective of this review is to summarize recent scientific and medical literature regarding chemoresponse assays or chemotherapy sensitivity and resistance assays (CSRAs), specifically as applied to epithelial ovarian cancer. A total of sixty-seven articles, identified through PubMed using the key words "in vitro chemoresponse assay," "chemo sensitivity resistance assay," "ATP," "HDRA," "EDR," "MiCK," and "ChemoFx," were reviewed. Recent publications on marker validation, including relevant clinical trial designs, were also included. Recent CSRA research and clinical studies are outlined in this review. Published findings demonstrate benefits regarding patient outcome with respect to recent CSRAs. Specifically, analytical and clinical validations, as well as clinical utility and economic benefit, of the most common clinically used CSRA in the United States support its use to aid in making effective, individualized clinical treatment selections for patients with ovarian cancer.
    Full-text · Article · Jul 2014 · Clinical and Translational Oncology
  • Source
    • "In women with a diagnosis of ovarian cancer, disease recurrence will eventually occur in 60 to 85% of cases within five years after primary treatment [1]. Intravenous chemotherapy with platinum compounds, taxanes, anthracyclines, gemcitabine, topotecan, and trabectedin in various combinations and sequences are the mainstay of recurrence treatment with median survival rates between 4 and 10 months [2]. Intraperitoneal chemotherapy (IPC) in the clinical setting of recurrent ovarian cancer is an experimental approach. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the activity of laparoscopic Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in women with recurrent, platinum-resistant ovarian cancer. Prospective case series using repeated courses q 28-42days of PIPAC containing cisplatin 7.5mg/m(2) and doxorubicin 1.5mg/m(2) at 12mmHg and 37°C for 30min. Objective tumor response was defined as tumor regression on histology and peritoneal carcinomatosis index (PCI) improvement on repeated video-laparoscopy. 34 PIPAC procedures were performed in 18 women, in 8 instances combined with cytoreductive surgery (CRS). Eight women had repeated PIPAC and objective tumor response was observed in 6 (complete remission:1; partial remission: 2; stable disease: 3). Five adverse events WHO grade ≥2 were noted, 3 of them after combined CRS. No perioperative mortality occurred. Median follow-up was 192days (min. 13 - max. 639). Cumulative survival after 400days was 62% and mean actuarial survival time was 442days. In a multivariable regression analysis with objective tumor response (yes vs. no) as the dependent variable and PIPAC (1 vs. >1), patient age (<75 vs. ≥75years), serum CA-125 (<1000 vs. >1000 U/mL), and presence of ascites (yes vs. no) as independent variables, PIPAC independently predicted objective tumor response. PIPAC has activity in women with recurrent, platinum-resistant ovarian cancer and should be investigated in prospective clinical trials.
    Full-text · Article · Nov 2013 · Gynecologic Oncology
  • Source

    Full-text · Article · · Revista Venezolana de Oncologia
Show more

We use cookies to give you the best possible experience on ResearchGate. Read our cookies policy to learn more.